Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China Kumar Jeetendra | June 28, 2019 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A …
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China Kumar Jeetendra | June 28, 2019 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A …
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China Kumar Jeetendra | June 28, 2019 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A …
Indias Biggest Pharma Expo in the National Capital Kumar Jeetendra | June 15, 2019 Indian Pharma Expo 2019 is coming up on 16th, 17th & 18th July at Hall 12A Pragati Maidan, New Delhi. New Delhi: India’s famous Pharma event “Indian Pharma Expo 2019” will be inaugurated on 16th July at HALL No. 12A, Pragati Maidan, New Delhi. At the time of inauguration Key dignitaries from Department of Pharmaceuticals, …
Dr Reddys Laboratories announces the relaunch of Zenatane in the US Market Kumar Jeetendra | June 3, 2019 Hyderabad, India and Princeton, NJ, USA. June 3, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the re-launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg a therapeutic equivalent generic version of Accutane®, …
Cipla receives final approval for generic version of Gilead Sciences Incs Letairis AmbrisentanTabs 5mg and 10mg Kumar Jeetendra | April 30, 2019 Mumbai, India; April 30, 2019: – Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce receipt of final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan Tablets 5mg & 10mg from the United States Food and Drug Administration (US FDA). rnrn rn Cipla’s Ambrisentan Tablets 5mg & 10mg …
Lupin in alliance with Natco receives FDA approval for Bosentan Tablets Kumar Jeetendra | April 30, 2019 Mumbai, Baltimore, April 30, 2019: Lupin Limited (Lupin) in alliance with Natco Pharma (Natco) announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Actelion Pharmaceuticals Limited’s Tracleer Tablets, 62.5 mg and 125 mg. rnrn Lupin …
Cipla appoints Dr Raju Mistry as Global Chief People Officer Kumar Jeetendra | April 22, 2019 Mumbai, April 22, 2019 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announces the appointment of Dr. Raju Mistry as President and Global Chief People Officer (GCPO) of Cipla. Raju is an accomplished and veteran Human Resources (HR) leader with over 27 years of global experience across diverse sectors …
Lupin receives FDA approval for Testosterone Gel Kumar Jeetendra | April 11, 2019 Mumbai, Baltimore, April 11, 2019: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s (AbbVie) AndroGel 1.62%. Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), …
Lupin launches Fluoxetine Tablets USP Kumar Jeetendra | April 10, 2019 Mumbai, Baltimore, April 10, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg. It is indicated in the …
Emcure launches worlds first generic Eribulin for treatment of metastatic breast cancer Kumar Jeetendra | April 4, 2019 Eribulin will be available in India at approximately 40% cost of the innovator brand Emcure Pharmaceuticals, a leading integrated global pharmaceutical company from India today announced the launch of the world’s first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) for the treatment of metastatic breast cancer (MBC). Emcure will be marketing the drug under brand …
Lupin Bioresearch Centre completes fifth successful US FDA inspection Kumar Jeetendra | April 3, 2019 Mumbai, Baltimore, April 03, 2019: Pharma major Lupin Limited (Lupin) announced the successful completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Lupin Bioresearch Centre (LBC) without any observations. rnrnThis is the fifth successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility. rnrnLupin …
